Forian Inc. Common Stock (FORA)
Fast GrowerFairStock Score: 41/100 — MIXED
Key Financials
| Current Price | $2.17 |
| Market Cap | $67M |
| P/E Ratio | -24.11 |
| ROE | -17.95% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $4 million in annual free cash flow (5.8% yield on market cap)
- Conservative balance sheet with debt-to-equity of just 0.00, providing financial flexibility
- Revenue growth of 37.0% demonstrates strong top-line momentum
Concerns
- Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
- Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions
AI Analysis
Forian Inc. Common Stock is a micro-cap healthcare company valued at $67 million. Revenue stands at $30 million, though the company is currently unprofitable. From a quality standpoint, Forian shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and Altman Z-Score of 2.0 in the grey zone. On valuation, the stock is solid 4.8% FCF yield. Growth dynamics show revenue growing at 37.0% and profit growth of -1012.2%. Our composite FairStock Score of 41/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.
Bull Case
Forian's 37% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $4 million in annual free cash flow (5.8% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer